Preeclampsia Risk and Prevention among Pregnant Medicaid Beneficiaries
Loading...
Links to Files
Collections
Author/Creator
Author/Creator ORCID
Date
2020-11
Type of Work
Department
Program
Citation of Original Publication
Cross-Barnet, Caitlin et al.; Preeclampsia Risk and Prevention among Pregnant Medicaid Beneficiaries; Journal of Health Care for the Poor and Underserved, Volume 31, Number 4, November 2020; https://doi.org/10.1353/hpu.2020.0123
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Public Domain Mark 1.0
This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law
Public Domain Mark 1.0
This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law
Subjects
Abstract
Pregnancy-related hypertensive disorders can cause morbidity and mortality. Low-dose aspirin (LDA) reduces risk. This paper aims to assess Medicaid beneficiaries' risk factors for preeclampsia and their providers' clinical use of LDA in the federal Strong Start for Mothers and Newborns II initiative. Twenty-seven awardees with more than 200 care sites served almost 46,000 women. This mixed-methods analysis assesses rates of risks, incidence of pregnancy-related hypertensive disorders, and assessment of care teams' LDA knowledge and reported prescription practices. Many Strong Start participants had risk factors that merited LDA, but most practices reported inconsistent or non-existent prescribing. Use varied within the three care models and among all provider types. Ancillary care team members often had no knowledge of LDA's benefits, resulting in lost opportunities for educating patients and assessing adherence to LDA use. Clear policies and well-integrated care teams could increase evidence-based use, improve pregnancy outcomes, and promote women's lifelong cardiovascular health.